Eli Lilly is suing four telehealth companies for allegedly selling compounded copies of the manufacturer’s tirzepatide weight loss drugs, Zepbound and Monjaro. The lawsuits filed Wednesday accuse the telehealth sites of deceiving consumers about “untested, unapproved drugs” and turning them away from Lilly’s name-brand medicines.

Complaints include allegations of switching patients to compounded medication with different additives or at different dosages than those offered by Lilly, and allegations of selling in untested forms (pills) that have not been approved by the FDA. One complaint addresses a false claim of having developed the first “cosmetic” GLP-1, a distinction not recognized by the FDA for tirzepatide.

Read more at NPR >>